JP2006514035A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514035A5
JP2006514035A5 JP2004562291A JP2004562291A JP2006514035A5 JP 2006514035 A5 JP2006514035 A5 JP 2006514035A5 JP 2004562291 A JP2004562291 A JP 2004562291A JP 2004562291 A JP2004562291 A JP 2004562291A JP 2006514035 A5 JP2006514035 A5 JP 2006514035A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
exendin
peptide
composition according
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004562291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514035A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/040504 external-priority patent/WO2004056313A2/en
Publication of JP2006514035A publication Critical patent/JP2006514035A/ja
Publication of JP2006514035A5 publication Critical patent/JP2006514035A5/ja
Pending legal-status Critical Current

Links

JP2004562291A 2002-12-17 2003-12-17 心不整脈の予防および治療 Pending JP2006514035A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43450802P 2002-12-17 2002-12-17
US43488802P 2002-12-19 2002-12-19
PCT/US2003/040504 WO2004056313A2 (en) 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias

Publications (2)

Publication Number Publication Date
JP2006514035A JP2006514035A (ja) 2006-04-27
JP2006514035A5 true JP2006514035A5 (enExample) 2006-11-30

Family

ID=32685317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004562291A Pending JP2006514035A (ja) 2002-12-17 2003-12-17 心不整脈の予防および治療

Country Status (4)

Country Link
EP (1) EP1610811A4 (enExample)
JP (1) JP2006514035A (enExample)
AU (1) AU2003297356A1 (enExample)
WO (1) WO2004056313A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1789440A4 (en) 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
DK1888103T3 (da) 2005-04-11 2012-04-23 Amylin Pharmaceuticals Inc Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
EP1922336B1 (en) * 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
MX2008015107A (es) * 2006-05-26 2008-12-09 Amylin Pharmaceuticals Inc Composicion y metodos para el tratamiento de insuficiecia cardiaca congestiva.
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
AU2008306190A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of bubuc and optionally EAA-MART1 (26-35) as a therapeutic agent for the treatment of HCMV infections
HUE031900T2 (en) 2008-12-10 2017-08-28 Glaxosmithkline Llc Pharmaceutical compositions containing Albiglutide
EP2566502A4 (en) 2010-05-04 2013-10-09 Glaxosmithkline Llc METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
EP2771025A1 (en) * 2011-10-28 2014-09-03 Pharis Biotec GmbH A polypeptide for the protection against heart ischemia-reperfusion injury
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
CN108939052B (zh) * 2018-09-04 2021-03-16 江苏省中医药研究院 艾塞那肽在制备预防或治疗房颤的药物中的用途
CN110551203B (zh) * 2019-09-25 2023-02-10 成都奥达生物科技有限公司 一种艾塞那肽类似物
TW202228762A (zh) * 2020-01-30 2022-08-01 美商美國禮來大藥廠 提派肽(tirzepatide)之治療用途
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
WO1999040788A1 (en) * 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
AU2001263230B2 (en) * 2000-05-19 2005-03-10 Amylin Pharmaceuticals, Llc Treatment of acute coronary syndrome with glp-1
CA2395165C (en) * 2000-10-20 2012-05-22 Mario Ehlers Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
WO2002085406A1 (en) * 2001-04-24 2002-10-31 Restoragen, Inc. Methods and compositions for treating conditions associated with insulin resistance

Similar Documents

Publication Publication Date Title
Jakubowska et al. The road towards triple agonists: glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and glucagon receptor-an update
KR101996739B1 (ko) 글루카곤 및 glp-1 수용체의 공-효능제
AU2016244202B2 (en) Pharmaceutical composition for treating a metabolic syndrome
DE60016393T2 (de) Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe
Chrysant et al. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors
EP3080150B1 (en) Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
AU2015243611B2 (en) Dual GLP-1 / glucagon receptor agonists derived from exendin-4
KR100518046B1 (ko) Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
EP3080154B1 (en) Dual glp-1/gip receptor agonists
US7259136B2 (en) Compositions and methods for treating peripheral vascular disease
CA2395165C (en) Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
US7790681B2 (en) Treatment of cardiac arrhythmias with GLP-1 receptor ligands
JP2005535569A5 (enExample)
Mudaliar et al. Incretin therapies: effects beyond glycemic control
WO2004056313A2 (en) Prevention and treatment of cardiac arrhythmias
WO2015086732A1 (en) Exendin-4 peptide analogues
Holst Incretin therapy for diabetes mellitus type 2
WO2017074798A2 (en) Long-acting co-agonists of the glucagon and glp-1 receptors
CN116970062A (zh) 一种超长效glp-1多肽衍生物及其制备方法和用途
Ahrén Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes
CN121969607A (zh) 用于治疗代谢疾病的sglt1抑制剂和肠降血糖素的组合
M McCormick et al. Cardiac protection via metabolic modulation: an emerging role for incretin-based therapies?
Bulushova et al. Incretin analogues in the therapy of type 2 diabetes and obesity
Alonso et al. GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives
Ismail et al. AN OVERVIEW OF INCRETIN-BASED THERAPIES: PHARMACOLOGY AND FUTURE PERSPECTIVES